Abstract
Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Australia / epidemiology
-
Breast Neoplasms / drug therapy*
-
Carboplatin / administration & dosage
-
Case-Control Studies
-
Cesarean Section
-
Cohort Studies
-
Congenital Abnormalities / epidemiology*
-
Continuous Positive Airway Pressure
-
Cyclophosphamide / administration & dosage
-
Docetaxel / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Gestational Age
-
Humans
-
Infant, Low Birth Weight
-
Infant, Newborn
-
Infant, Small for Gestational Age
-
Labor, Induced
-
New Zealand / epidemiology
-
Paclitaxel / administration & dosage
-
Perinatal Death*
-
Pregnancy
-
Pregnancy Complications, Neoplastic / drug therapy*
-
Pregnancy Trimester, First
-
Pregnancy Trimester, Second
-
Premature Birth / epidemiology*
-
Prospective Studies
-
Respiratory Distress Syndrome, Newborn / epidemiology
-
Respiratory Distress Syndrome, Newborn / therapy
-
Stillbirth / epidemiology*
-
Tamoxifen / administration & dosage
-
Trastuzumab / administration & dosage
Substances
-
Tamoxifen
-
Docetaxel
-
Doxorubicin
-
Cyclophosphamide
-
Carboplatin
-
Trastuzumab
-
Paclitaxel